185 related articles for article (PubMed ID: 21804474)
1. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials.
Ji XQ; Ruan XJ; Chen H; Chen G; Li SY; Yu B
Med Sci Monit; 2011 Aug; 17(8):RA169-176. PubMed ID: 21804474
[TBL] [Abstract][Full Text] [Related]
2. Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials.
Guo TK; Hao XY; Ma B; Yang KH; Li YP; Li HL; Gu YH; Cai H; Liu YL; Li Y; Zhan WP
J Cancer Res Clin Oncol; 2009 Dec; 135(12):1685-92. PubMed ID: 19536563
[TBL] [Abstract][Full Text] [Related]
3. Octreotide therapy for hepatocellular carcinoma: a systematic review of the evidence from randomized controlled trials.
Jia WD; Zhang CH; Xu GL; Ge YS; Wang W
Hepatogastroenterology; 2010; 57(98):292-9. PubMed ID: 20583430
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.
Kouroumalis E; Skordilis P; Thermos K; Vasilaki A; Moschandrea J; Manousos ON
Gut; 1998 Mar; 42(3):442-7. PubMed ID: 9577356
[TBL] [Abstract][Full Text] [Related]
5. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.
Becker G; Allgaier HP; Olschewski M; Zähringer A; Blum HE;
Hepatology; 2007 Jan; 45(1):9-15. PubMed ID: 17187405
[TBL] [Abstract][Full Text] [Related]
6. [Somatostatin analogue (octreotide)].
Sano K; Makuuchi M
Nihon Rinsho; 2001 Oct; 59 Suppl 6():674-7. PubMed ID: 11762035
[No Abstract] [Full Text] [Related]
7. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations.
Abdel-Rahman O; Lamarca A; Valle JW; Hubner RA
Endocr Relat Cancer; 2014; 21(6):R485-93. PubMed ID: 25336571
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature.
Reynaert H; Colle I
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569719
[TBL] [Abstract][Full Text] [Related]
9. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial.
Dimitroulopoulos D; Xinopoulos D; Tsamakidis K; Zisimopoulos A; Andriotis E; Panagiotakos D; Fotopoulou A; Chrysohoou C; Bazinis A; Daskalopoulou D; Paraskevas E
World J Gastroenterol; 2007 Jun; 13(23):3164-70. PubMed ID: 17589893
[TBL] [Abstract][Full Text] [Related]
10. Octreotide in hepatocellular carcinoma.
Shouval D
Gut; 1998 Mar; 42(3):316-7. PubMed ID: 9577332
[No Abstract] [Full Text] [Related]
11. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing?
Hejna M; Schmidinger M; Raderer M
Ann Oncol; 2002 May; 13(5):653-68. PubMed ID: 12075733
[TBL] [Abstract][Full Text] [Related]
12. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
Yuen MF; Poon RT; Lai CL; Fan ST; Lo CM; Wong KW; Wong WM; Wong BC
Hepatology; 2002 Sep; 36(3):687-91. PubMed ID: 12198662
[TBL] [Abstract][Full Text] [Related]
13. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.
Peng S; Zhao Y; Xu F; Jia C; Xu Y; Dai C
PLoS One; 2014; 9(12):e112530. PubMed ID: 25460347
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.
Cebon J; Findlay M; Hargreaves C; Stockler M; Thompson P; Boyer M; Roberts S; Poon A; Scott AM; Kalff V; Garas G; Dowling A; Crawford D; Ring J; Basser R; Strickland A; Macdonald G; Green M; Nowak A; Dickman B; Dhillon H; Gebski V;
Br J Cancer; 2006 Oct; 95(7):853-61. PubMed ID: 16953241
[TBL] [Abstract][Full Text] [Related]
15. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
[TBL] [Abstract][Full Text] [Related]
16. Treatment of hepatocellular carcinoma with long acting somatostatin analogues.
Samonakis DN; Moschandreas J; Arnaoutis T; Skordilis P; Leontidis C; Vafiades I; Kouroumalis E
Oncol Rep; 2002; 9(4):903-7. PubMed ID: 12066229
[TBL] [Abstract][Full Text] [Related]
17. [A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide].
Allgaier HP; Becker G; Blum HE
Dtsch Med Wochenschr; 2000 Mar; 125(11):320. PubMed ID: 10761474
[No Abstract] [Full Text] [Related]
18. Hepatocellular carcinoma and octreotide: treatment results in prospectively assigned patients with advanced tumor and cirrhosis stage.
Plentz RR; Tillmann HL; Kubicka S; Bleck JS; Gebel M; Manns MP; Rudolph KL
J Gastroenterol Hepatol; 2005 Sep; 20(9):1422-8. PubMed ID: 16105131
[TBL] [Abstract][Full Text] [Related]
19. The Use of Prophylactic Somatostatin Therapy Following Pancreaticoduodenectomy: A Meta-analysis of Randomised Controlled Trials.
Adiamah A; Arif Z; Berti F; Singh S; Laskar N; Gomez D
World J Surg; 2019 Jul; 43(7):1788-1801. PubMed ID: 30798417
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken.
Samonakis DN; Notas G; Christodoulakis N; Kouroumalis EA
Dig Dis Sci; 2008 Sep; 53(9):2359-65. PubMed ID: 18273705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]